Low Dose Methotrexate
Phase 2Small molecule
Low Dose Methotrexate is one of 63 small molecule programs targeting Childhood Acute Lymphoblastic Leukemia. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
201 competitors in Follicular Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Fludara
SanofiPhase 3
Zydelig
GileadPhase 3
Rayos
RRoxane Laboratories
Phase 3
Kesimpta
NovartisPhase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Leukeran
Akero TherapeuticsPhase 3
Mabthera
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Childhood Acute Lymphoblastic Leukemia1 trial
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008
Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·N/A·NCT01953770·3,000 enrolled
Vascular Inflammation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Low Dose Methotrexate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital